Streetbeat News

Regulatory

GSK

PFE

The FDA has approved Pfizer's RSV vaccine, Abrysvo, for adults aged 18-59 at high risk, expanding its previous indication for those 60 and older. This approval is based on the Phase 3 MONeT study. Pfizer aims to publish these results and present them at a conference. Despite the approval, sales of RSV vaccines from Pfizer and GSK have declined due to regulatory changes. Pfizer's stock is slightly down.

Portfolio Pulse from Vandana Singh

October 23, 2024 | 3:31 pm

FTNT

Fortinet has disclosed a critical vulnerability in its FortiManager API, identified as CVE-2024-47575, which has been exploited in zero-day attacks. The flaw allows attackers to steal sensitive files, including configurations and credentials. Fortinet warned customers privately before the news leaked online.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 3:09 pm

AAPL

GS

The CFPB has ordered Apple and Goldman Sachs to pay over $89 million for mishandling Apple Card transaction disputes and misleading consumers about interest-free payment options. The companies failed to properly manage disputes and misled customers about interest-free plans, resulting in penalties and restrictions.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 2:12 pm

CNSP

CNS Pharmaceuticals (CNSP) stock surged 86% after receiving a Nasdaq notice for failing to meet the $1.00 minimum bid price requirement. The company is ineligible for a 180-day extension due to past reverse stock splits and has requested a hearing on November 5 to delay delisting.

Portfolio Pulse from Henry Khederian

October 23, 2024 | 2:08 pm

BFLBF

HOCFF

KSVRF

The European economy is facing stagflation despite cooling inflation, with PMI and sentiment indicators declining. The ECB may continue cutting interest rates, but the outlook remains bleak. Foreign takeovers of German companies are increasing due to lower valuations.

Portfolio Pulse from European Capital Insights

October 23, 2024 | 1:59 pm

JNJ

The European Commission has approved a new DARZALEX-SC based quadruplet regimen for patients with newly diagnosed multiple myeloma who are transplant-eligible. This approval is based on the Phase 3 PERSEUS study, which showed a significant reduction in the risk of disease progression or death.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 1:58 pm

MSOS

MSOX

YOLO

AdvisorShares MSOS ETF surged 8% as cannabis rescheduling discussions and potential regulatory changes spark investor interest. The ETF, focusing on U.S. cannabis companies, broke above key moving averages, indicating strong momentum but potential short-term pullback.

Portfolio Pulse from Rolando García

October 23, 2024 | 1:32 pm

FAMI

Farmmi shares rose as NASDAQ granted the company a 180-day extension to comply with the minimum bid price requirement.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 1:32 pm

BABA

BIDU

LI

NIO

XPEV

ZK

The IMF has downgraded China's 2024 economic growth forecast, impacting US-listed Chinese EV stocks like NIO, Li Auto, XPeng, and ZEEKR, which are trading higher in anticipation of more Chinese stimulus. Meanwhile, stocks like Alibaba and Baidu remain restrained.

Portfolio Pulse from Anusuya Lahiri

October 23, 2024 | 1:16 pm

CNSP

CNS Pharmaceuticals shares are trading higher following the company's request for a panel hearing on November 5, 2024. The decision on suspension or delisting will be on hold until the hearing.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 1:15 pm